0 seconds of 2 minutes, 56 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
02:56
02:56
 
  • PreveCeutical (PREV) files a PCT (Patent Cooperation Treaty) application for D-amino acid peptides
  • The patent aims to seek protection for certain peptides comprising D-amino acids and their use in treating brain cancer
  • This patent application is made to protect the peptides comprising D-amino acids identified in the BSV research project
  • These peptides have the potential, at least in part, to work as an MMP inhibitor
  • CEO Stephen Van Deventer sat down with Sabrina Cuthbert to discuss the news
  • PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural identical products
  • PreveCeutical Medical (PREV) opened trading at C$0.025

PreveCeutical Medical (PREV) filed a PCT (Patent Cooperation Treaty) application number on November 18.

The company aims to be a leader in the preventive health sciences sector.

For this application, the company entitled the patent, “Peptides and Uses Thereof,” which aims to seek protection for certain peptides comprising D-amino acids and their use in treating brain cancer.

D-Amino is an amino acid comprising d-serine and d-aspartate. Found in the human body, they are the two most commonly studied acids in the human body.

This patent application is made to protect the peptides comprising D-amino acids identified in the BSV research project.

These peptides have the potential, at least in part, to work as an MMP inhibitor.

Stephen Van Deventer has assigned any and all of its rights in the invention and patent to the company.

CEO Stephen Van Deventer sat down with Sabrina Cuthbert to discuss the news.

“This patent will protect the peptides which have the potential for cancer treatments. We are actively seeking partners to work with for these treatments. As my further dedication and commitment to PreveCeutical, I have assigned my inventor and patent rights to the company free of charge.”

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural identical products.

PreveCeutical Medical (PREV) opened trading at C$0.025

Latest News
More V.ELO news on Stockhouse »
Latest Bullboard Posts
More bullboard posts for V.ELO on Stockhouse »
More From The Market Online
BriaCell logo

BriaCell’s Bria-OTS shows sustained success against breast cancer

BriaCell (TSX:BCT) announces the resolution of the lung metastasis first reported in February in a 78-year-old woman with breast cancer.

Buzz on the Bullboards: Quarterly success stories and struggles

Whitecap Resources, Aecon Group, and WELL Health Technologies have reported developments and results that could impact their performance.
Image via Hapbee Technologies Inc

Hapbee Technologies to rollout new ‘Boosted Signals’ feature

Hapbee Technologies (TSXV:HAPB) is rolling out a new feature—Boosted Signals—as part of the company’s redesigned mobile...
Prototype of Hypha Labs' Mushroom Accelerator

Hypha Labs and the technology behind micropearls

Hypha Labs (OTCQB:FUNI), a Vegas-based innovator, is the frontrunner in the race to democratize the benefits of functional mushrooms.